Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.

ABSTRACT:

Purpose

Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications.

Methods

RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies).

Results

Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutan

SUBMITTER: Fernandez Montes A 

PROVIDER: S-EPMC9107427 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature